Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Ana... (n a number of malignancies including col...)

Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event

Date:9/24/2009

n a number of malignancies including colon cancer and is targeted for entry into clinical trials in 2012, fulfilling our goal of entering one new ACI into the clinic each year for the next three years.

About PROVENGE

PROVENGE is Dendreon's investigational product candidate for men with advanced prostate cancer and may represent the first in a new class of ACIs specifically designed to engage the patient's own immune system against cancer. PROVENGE and other ACIs are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. Dendreon recently announced that the pivotal Phase 3 IMPACT study of PROVENGE in men with advanced prostate cancer met its primary endpoint of improving overall survival compared to a placebo control.

Webcast Replay Information

If you are interested in listening to the replay of the analyst day webcast, you may access it from the Company's website at www.dendreon.com under the "Investor/Webcasts and Presentations" section.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce ACI product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington, and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
2. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
3. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
4. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
5. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
6. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
7. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
8. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
9. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
10. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
11. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer

Post Your Comments:

(Date:11/20/2009)... MINNEAPOLIS, Nov. 20 Bi...ults for its first quarter ended September 30, 200...ted share, on revenues of $3,263,000. This compar...ed share, on revenues of $3,168,000 for the first ...t quarter results, Biotel President and CEO Steve ...

(Date:11/20/2009)..., FRANKLIN LAKES, N.J., Nov. 20 /PRNewswire-FirstC... BDX ) today announced the completion of its acqu...based company that develops and manufactures molec..., In May 2009, BD and HandyLab announced an exc...ze molecular assays on the HandyLab Jaguar(TM) pla...

(Date:11/19/2009)..., ARDEE, Ireland, Nov. 19 Warner ...pricing of its previously announced secondary offe...ce to the public of $22.25 per share. The selling...apital Partners, DLJ Merchant Banking, J.P. Morgan...Lee Partners, L.P., certain other institutional in...

Breaking Medicine Technology:Biotel Announced Profitable First Quarter Ended September 30, 2009 2 BD Completes Acquisition of HandyLab, Inc. 2 BD Completes Acquisition of HandyLab, Inc. 3 Warner Chilcott Prices Secondary Equity Offering 2 Warner Chilcott Prices Secondary Equity Offering 3 Warner Chilcott Prices Secondary Equity Offering 4 Lupin Expands Branded Play 5066 1 Lupin Expands Branded Play 5066 2 Lupin Expands Branded Play 5066 3 Sexually satisfied women have better general well being and more vitality 58485 1 Sexually satisfied women have better general well being and more vitality 58485 2 Sexually satisfied women have better general well being and more vitality 58485 3 Is trash the solution to tackling climate change 3F 14282 1

[0] Biotel Announced Profitable First Quarter Ended September 30, 2009 [0] BD Completes Acquisition of HandyLab, Inc.[0] Warner Chilcott Prices Secondary Equity Offering

...E) -- MGI PHARMA, INC.,(NASDAQ:MOGN), a biopharmac..., today announced the presentation of results of a...ospropofol,disodium) Injection in patients undergo...dpoint results, as well as safety data, were,prese... D.C. by,Lawrence B. Cohen, MD, Department of Medi...

...ms and Urine Flow, With,Long Lasting Effect in Pha...re-FirstCall/ -- Spectrum,Pharmaceuticals, Inc., t...r ozarelix, the Company,s drug candidate for the t... the American Urology,Association Annual Meeting h...alifornia on Tuesday, May 22, 2007. , "The results...

Other Medicine Technology:Aquavan (Fospropofol Disodium) Injection Data Presented at,Digestive Disease Week 2007 2 Aquavan (Fospropofol Disodium) Injection Data Presented at,Digestive Disease Week 2007 3 Aquavan (Fospropofol Disodium) Injection Data Presented at,Digestive Disease Week 2007 4 Aquavan (Fospropofol Disodium) Injection Data Presented at,Digestive Disease Week 2007 5 Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 2 Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 3 Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 4 Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 5

Aquavan (Fospropofol Disodium) Injection Data Presented at,Digestive Disease Week 2007 Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association

(Date:11/21/2009)... Eric J. Hall, president and chief execu...ica (AFA) issued the following statement regarding...s part of the new annual wellness for Medicare ben...ordable Care Act" that was introduced last ni...B) November 21, 2009 -- Eric J. Hall, president an...

(Date:11/21/2009)... Linwood Group ask whether there is a se...ured? , London, UK (PRWEB...ith up to one in three of the adult UK population ...ping alcohol-related liver disease*, it is hardly ...ehabilitation programmes and residential centres f...

(Date:11/20/2009)...NCETON, NJ, Nov. 20 /PRNewswire-FirstCall/ - NUCRY...ecial Meeting of Shareholders will be held on Mond...is to consider approval of two special resolutions...uthorize the sale of all or substantially all of t...rovided for in the asset purchase agreement dated ...

(Date:11/20/2009)... WASHINGTON, Nov. 20 Th...ed the Senate to make essential changes its health... on abortion funding and conscience protection on ...ants and include strong provisions for adequate af...ealth care bill an "enormous disappointment" that ...

(Date:11/20/2009)... Senators and Congressmen in Competitive...r Health Care Vote , Wash...nd congressmen running for re-election next year i... Charlie Cook, may come to regret voting for House...cording to a breaking Zogby International/ O&rsquo...

Breaking Medicine News(10 mins):Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 2 Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 3 Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 2 Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 3 Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 4 Health News:NUCRYST Announces Special Meeting of Shareholders 2 Health News:NUCRYST Announces Special Meeting of Shareholders 3 Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2 Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2 Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3

[0] Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform [0] Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not [0] NUCRYST Announces Special Meeting of Shareholders [0] U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability [0] Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill

...CAGO and HARTFORD, Conn., Feb. 13 ,Allscripts, the...ty and,information solutions that physicians use t...th Physicians, the largest primary care medical gr...nical,and administrative processes., (Logo: http...

...ble amputee Oscar Pistorius files appeal challengi...tion (IAAF); seeks qualification at ...scar Pistorius -- a double amputee,athlete from So...witzerland challenging the International Associati...

... Sutent,s benefits may still outweigh its risks fo..., Feb. 13 (HealthDay News) -- A greater percentage...eart failure when taking the breakthrough cancer d...ole for routine cardiac monitoring for patients re...

...ffirms Outlook for Continued Growth, CAMBRIDGE, M...) today reported financial results for the full ye...ook for continued strong growth,in 2008 and beyond... growth across all segments of the company., ...

...NZHEN, China, Feb. 13 /Xinhua-PRNewswire/ -- Winne...inner Medical"), reported today the,consolidated f...ear 2008,ended December 31, 2007. The Company,s re...lidated net sales of $19.33 million, a 21.73% year...

...NCETON, N.J., Feb. 13 Pharmacopeia,(Nasdaq: PCOP...of novel,small molecule therapeutics, today announ...Executive Officer, will deliver a corporate,presen... Point, CA., Dr. Browne,s presentation will take ...

ProHealth Physicians Selects Allscripts Electronic Health Record and Practice Management for 240 Providers Oscar Pistorius Aims to Compete on Level Playing Field at 2008 Beijing Olympics Kidney Cancer Drug Linked to Higher Rate of Heart Problems Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year Winner Medical Reports First Quarter Fiscal 2008 Results Pharmacopeia to Present at The Roth 20th Annual OC Growth Stock Conference

...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...

Medicine Products:

Human Monocytic Ehrlichiosis (HME), HME Antibody IgG & IgM Human Monocytic Ehrlichiosis (HME), HME Antibody IgG Human Immunodeficiency Virus 2 Antibody Confirmation by IFA Human Immunodeficiency Virus 1, vircoTYPE

Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Ana...(n a number of malignancies including col...),Health